LoSeasonique

LoSeasonique is a brand name of ethinyl estradiol/levonorgestrel, approved by the FDA in the following formulation(s):

LOSEASONIQUE (ethinyl estradiol; levonorgestrel - tablet; oral)

• 
  Manufacturer: TEVA WOMENS
  
  Approval date: October 24, 2008
  
  Strength(s): 0.02MG,0.01MG;0.1MG,N/A ^[AB]

Has a generic version of LoSeasonique been approved?

A generic version of LoSeasonique has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to LoSeasonique and have been approved by the FDA:

LEVONORGESTREL AND ETHINYL ESTRADIOL (ethinyl estradiol; levonorgestrel tablet; oral)

• 
  Manufacturer: LUPIN LTD
  
  Approval date: October 26, 2011
  
  Strength(s): 0.02MG,0.01MG;0.1MG,N/A ^[AB]


• 
  Manufacturer: WATSON LABS
  
  Approval date: October 25, 2011
  
  Strength(s): 0.02MG,0.01MG;0.1MG,N/A ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of LoSeasonique. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
  Patent 7,615,545
  Issued: November 10, 2009
  Inventor(s): Bell; Robert G. & Ben-Maimon; Carole & Iskold; Beata
  Assignee(s): Duramed Pharmaceuticals, Inc.
  This invention relates to a method of preventing pregnancy and treating PMS including PMDD. More particularly, the invention relates to a method, which involves administering one of several combination oral contraceptive regimens in combination with an antidepressant and a kit containing the same.
  
  Patent expiration dates:
  
  
  • June 15, 2023
    
    ✓ 
    Patent use: PREVENTION OF PREGNANCY
  
  



• 
  Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
  Patent 7,855,190
  Issued: December 21, 2010
  Inventor(s): Bell; Robert G. & Ben-Maimon; Carole S. & Iskold; Beata & Bronnenkant; Lance J. & Hait; Howard & Reape; Kathleen Z.
  Assignee(s): Teva Women's Health, Inc.
  The present invention provides contraceptive regimens in which a female is administered a combined dosage form of estrogen and progestin followed by a period of administration of estrogen. The disclosed contraceptive regimens can be administered to a female as a method of providing non-contraceptive benefits.
  
  Patent expiration dates:
  
  
  • December 5, 2028
    
    ✓ 
    Patent use: PREVENTION OF PREGNANCY
  
  



• 
  Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
  Patent 7,858,605
  Issued: December 28, 2010
  Inventor(s): Bell; Robert G. & Ben-Maimon; Carole & Iskold; Beata
  Assignee(s): Teva Women's Health, Inc.
  This invention relates to a method of preventing pregnancy and treating PMS including PMDD. More particularly, the invention relates to a method, which involves administering one of several combination oral contraceptive regimens in combination with an antidepressant and a kit containing the same.
  
  Patent expiration dates:
  
  
  • June 23, 2023
    
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • October 24, 2011 - NEW PRODUCT
  
  

See also...

• LoSeasonique Consumer Information (Drugs.com)
• LoSeasonique Consumer Information (Wolters Kluwer)
• LoSeasonique extended-cycle Consumer Information (Cerner Multum)
• Levonorgestrel/Ethinyl Estradiol Consumer Information (Wolters Kluwer)
• Ethinyl estradiol and levonorgestrel Consumer Information (Cerner Multum)
• Ethinyl estradiol and levonorgestrel extended-cycle Consumer Information (Cerner Multum)